FibroGen (FGEN) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. LYB
3. CRWD
4. TFII
5. LITE
6. CL
7. BP
8. ABBV
9. RELIANCE:I
10. NVT

Go back to FibroGen (FGEN) Tops Q2 EPS by 10c

FibroGen (FGEN) Announces Publication of Roxadustat Phase 2a Safety Data

August 13, 2015 6:58 AM EDT

FibroGen (NASDAQ: FGEN) announced that Nephrology Dialysis Transplantation has published encouraging Phase 2a safety and efficacy data for roxadustat, an orally active potent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of anemia associated with chronic kidney disease (CKD). In a multicenter, randomized, placebo-controlled trial that was conducted in non-dialysis subjects with anemia associated with stage 3 or 4 CKD, roxadustat produced dose-dependent increases in hemoglobin (Hb) within 14 to 25 days.

"To our knowledge, this publication is the first peer-reviewed article to feature a HIF-PHI, a new class of drug, in a... More